John D. Dobak
Net Worth

Last updated:

What is John D. Dobak net worth?

The estimated net worth of Dr. John D. Dobak is at least $8,367,152 as of 13 Mar 2023. He has earned $4,360,592 from insider trading and has received compensation worth at least $4,006,560 in DermTech, Inc..

What is the salary of John D. Dobak?

Dr. John D. Dobak salary is $667,760 per year as Pres, Chief Executive Officer & Director in DermTech, Inc..

How old is John D. Dobak?

Dr. John D. Dobak is 59 years old, born in 1966.

What stocks does John D. Dobak currently own?

As insider, Dr. John D. Dobak owns shares in one company:

Company Title Shares Price per share Total value
DermTech, Inc. (DMTK) Pres, Chief Executive Officer & Director 698,693 $0 $0

What does DermTech, Inc. do?

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

DMTK logo
DMTK
DermTech, Inc.

John D. Dobak insider trading

DermTech, Inc.

Dr. John D. Dobak has made 23 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,118 units of DMTK stock worth $10,165 on 13 Mar 2023.

The largest trade he's ever made was exercising 155,720 units of DMTK stock on 31 Dec 2019. As of 13 Mar 2023 he still owns at least 698,693 units of DMTK stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,118 $3.26 $10,165
Sale
Common Stock 23,246 $4.06 $94,379
Sale
Common Stock 709 $4.06 $2,879
Sale
Common Stock 1,326 $14.55 $19,293
Sale
Common Stock 786 $12.64 $9,935
Sale
Common Stock 2,561 $13.03 $33,370
Sale
Common Stock 1,964 $16.71 $32,818
Sale
Common Stock 1,119 $18.46 $20,657
Sale
Common Stock 1,899 $36.19 $68,725
Sale
Common Stock 1,162 $36.19 $42,053
Sale
Common Stock 12,500 $41.22 $515,288
Sale
Common Stock 7,651 $41.08 $314,326
Sale
Common Stock 1,118 $43.43 $48,555
Sale
Common Stock 9,530 $40 $381,200
Sale
Common Stock 2,970 $40.22 $119,444
Sale
Common Stock 25,000 $41.5 $1,037,425
Sale
Common Stock 25,000 N/A N/A
Sale
Common Stock 25,000 $15.97 $399,175
Sale
Common Stock 25,000 $46.88 $1,171,875
Sale
Common Stock 780 $50.04 $39,031
Sale
Common Stock 786 N/A N/A
Sale
Common Stock 2,470 N/A N/A
Sale
Common Stock 2,470 N/A N/A
Option
Restricted Stock Units 155,720 N/A N/A
Option
Common Stock 155,720 N/A N/A

DermTech key executives

DermTech, Inc. executives and other stock owners filed with the SEC:

  • Dr. John D. Dobak (59) Pres, Chief Executive Officer & Director
  • Mr. Kevin Sun M.B.A. (47) Chief Financial Officer, Treasurer & Sec.
  • Ms. Claudia Ibarra (63) Chief Operating Officer